Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma [Phase 3]
Phase 3 trial comparing fixed-duration versus continuous anti-CD38 monoclonal antibody therapy in transplant-ineligible older adults with ne…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating FT836 CAR T-cell therapy in combination with daratumumab for relapsed or refractory multiple myeloma; stat…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" [Phase 2]
This is a Phase 2 trial evaluating radiotherapy-induced immune priming to enhance Elranatamab in relapsed/refractory multiple myeloma with e…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) [Phase 1]
Phase 1 trial update evaluating adverse events, changes in disease activity, tolerability, and pharmacokinetics of intravenous ABBV-438 in a…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Collection of Tissue Samples for Cancer Research
This recruiting trial aims to collect tissue samples for cancer research, sponsored by the National Cancer Institute. It encompasses neoplas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial to assess safety and efficacy of HDP-101 in Chinese patients with relapsed or refractory multiple myeloma, currently recruit…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma [Phase 3]
A Phase 3 clinical trial is evaluating the efficacy, safety, and pharmacokinetics of XEMBIFY plus standard medical treatment (SMT) versus pl…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy [Phase 3]
Phase 3 study comparing VRd induction followed by cilta-cabtagene autoleucel (cilta-cel) CAR-T therapy versus Rd therapy in newly diagnosed …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating teclistamab monotherapy against PVd or Kd in relapsed or refractory multiple myeloma; study status is active but …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
A Phase 3 clinical trial comparing JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody in relapsed or refractory multiple myeloma is curr…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial update describing a study of four medicines (Elranatamab plus carfilzomib and dexamethasone or Maplirpacept) in adu…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma [Phase 3]
Phase 3 clinical trial update evaluating Teclistamab in combination with Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in combinatio…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma [Phase 1]
This document reports a Phase 1 clinical trial update on the combination of telaglenastat (CB-839) with carfilzomib and dexamethasone for pa…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance [Phase 2]
A Phase 2 trial evaluating measurable residual disease-guided post-transplant maintenance with elranatamab for multiple myeloma. The study i…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment [Phase 1, Phase 2]
A Phase 1/2 clinical trial comparing Teclistamab plus Pomalidomide against the standard Carfilzomib-Pomalidomide-Dexamethasone in patients w…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating subcutaneous daratumumab regimens in combination with bispecific T cell redi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma [NA]
This trial update covers a Mayo Clinic study evaluating remote monitoring with health coaching to improve quality of life in older adults wi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 clinical trial update evaluating sequences of cilta-cabtagene autoleucel and talquetamab in combination with daratumumab, and teclis…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel [Phase 2]
Ongoing Phase 2 clinical trial evaluating ciltacabtagene autoleucel (Carvykti) for multiple myeloma; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events [Phase 2]
A Phase 2 clinical trial is evaluating preventive treatments for GPRC5D-related oral events in patients with multiple myeloma, and the study…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma [Phase 1]
Phase 1 study of talquetamab in combination with other anticancer therapies for multiple myeloma; the trial is currently active but not recr…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
The study on biospecimen collection to identify genetic changes in patients with various cancers undergoing surgery is currently suspended; …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial evaluating adaptive dual-target CAR-T cell therapy for relapsed or refractory hematologic malignancies; recru…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
Clinical trial update assessing the diagnostic performance of a spot urine sample for detecting monoclonal components in patients with multi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
This update describes a Phase 2 trial of talquetamab in participants with relapsed or refractory multiple myeloma that is currently recruiti…